SOTERA HEALTH COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.4 USD | +0.71% |
|
+4.11% | -32.34% |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
| Apr. 03 | Citigroup Upgrades Sotera Health to Buy From Neutral, Cuts Price Target to $16 From $18 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,802 | 6,663 | 2,350 | 4,762 | 3,227 | - | - |
| Enterprise Value (EV) 1 | 9,560 | 8,341 | 3,976 | 6,767 | 5,160 | 5,013 | 3,227 |
| P/E ratio | -172 x | 57.4 x | -10 x | 93.6 x | 33.3 x | 22 x | 16.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.54 x | 7.15 x | 2.34 x | 4.54 x | 2.93 x | 2.74 x | 2.56 x |
| EV / Revenue | 11.7 x | 8.95 x | 3.96 x | 6.45 x | 4.69 x | 4.26 x | 2.56 x |
| EV / EBITDA | 22.8 x | 17.3 x | 7.85 x | 12.8 x | 9.29 x | 8.35 x | 4.96 x |
| EV / FCF | 143 x | 46.5 x | 41.6 x | -18.7 x | 24.7 x | 17.2 x | - |
| FCF Yield | 0.7% | 2.15% | 2.4% | -5.36% | 4.05% | 5.82% | - |
| Price to Book | 14.4 x | 11.4 x | 6.72 x | 10.7 x | 6.12 x | 4.79 x | - |
| Nbr of stocks (in thousands) | 284,321 | 282,917 | 282,113 | 282,623 | 283,071 | - | - |
| Reference price 2 | 27.44 | 23.55 | 8.330 | 16.85 | 11.40 | 11.40 | 11.40 |
| Announcement Date | 3/9/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 778.3 | 818.2 | 931.5 | 1,004 | 1,049 | 1,101 | 1,177 | 1,260 |
| EBITDA 1 | - | 419.9 | 481.2 | 506.2 | 528 | 555.5 | 600.1 | 650.3 |
| EBIT 1 | - | 356.6 | 417.1 | 442.2 | 451.5 | 481 | 520.3 | 563.4 |
| Operating Margin | - | 43.58% | 44.77% | 44.06% | 43.02% | 43.69% | 44.19% | 44.7% |
| Earnings before Tax (EBT) | - | -38.86 | 175.7 | - | - | - | - | - |
| Net income 1 | -20.85 | -38.62 | 116.9 | -233.6 | 51.38 | 97.03 | 148.6 | 207 |
| Net margin | -2.68% | -4.72% | 12.55% | -23.27% | 4.9% | 8.81% | 12.62% | 16.43% |
| EPS 2 | - | -0.1600 | 0.4100 | -0.8300 | 0.1800 | 0.3418 | 0.5177 | 0.7100 |
| Free Cash Flow 1 | - | 67.08 | 179.4 | 95.58 | -362.7 | 209 | 292 | - |
| FCF margin | - | 8.2% | 19.26% | 9.52% | -34.57% | 18.99% | 24.8% | - |
| FCF Conversion (EBITDA) | - | 15.98% | 37.28% | 18.88% | - | 37.63% | 48.66% | - |
| FCF Conversion (Net income) | - | - | 153.47% | - | - | 215.39% | 196.55% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 9/2/20 | 3/9/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 226.2 | 241.2 | 236.8 | 266.6 | 248.7 | 251.6 | 220.6 | 255.3 | 263.2 | 310.2 | 244.6 | 276.7 | 279.2 | 300.6 | 259 |
| EBITDA 1 | 116.7 | 124.7 | 115.3 | 136.1 | 125.2 | 129.6 | 98.47 | 128.5 | 134.3 | 166.7 | 116.6 | 139.5 | 142.4 | 156.6 | 125 |
| EBIT 1 | 100.3 | 108 | 99.48 | 120.4 | 109.3 | 113.1 | 79.54 | 109.5 | 116.3 | 146.1 | 97.16 | 120.6 | 124.3 | 138.7 | 103 |
| Operating Margin | 44.34% | 44.76% | 42.02% | 45.15% | 43.93% | 44.96% | 36.06% | 42.89% | 44.2% | 47.09% | 39.73% | 43.61% | 44.5% | 46.14% | 39.77% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 27.44 | 36 | 30.64 | 30.42 | 25.09 | -319.7 | 2.842 | 23.51 | -13.66 | 38.68 | 11.25 | 28.9 | 31.05 | 41.9 | 20 |
| Net margin | 12.13% | 14.92% | 12.94% | 11.41% | 10.09% | -127.08% | 1.29% | 9.21% | -5.19% | 12.47% | 4.6% | 10.45% | 11.12% | 13.94% | 7.72% |
| EPS 2 | 0.1000 | 0.1300 | 0.1100 | 0.1100 | 0.0900 | -1.140 | 0.0100 | 0.0800 | -0.0500 | 0.1400 | 0.0343 | 0.0812 | 0.0946 | 0.1319 | 0.0700 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/1/22 | 5/5/22 | 8/4/22 | 11/2/22 | 2/28/23 | 5/3/23 | 8/3/23 | 11/1/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1,758 | 1,679 | 1,626 | 2,005 | 1,932 | 1,786 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 4.188 x | 3.488 x | 3.212 x | 3.796 x | 3.479 x | 2.976 x | - |
| Free Cash Flow 1 | - | 67.1 | 179 | 95.6 | -363 | 209 | 292 | - |
| ROE (net income / shareholders' equity) | - | - | 47.3% | 57.7% | 58% | 38.7% | 35.1% | 28.4% |
| ROA (Net income/ Total Assets) | - | 3.71% | 8.86% | 9.15% | 7.37% | 8.28% | 9.43% | - |
| Assets 1 | - | -1,041 | 1,320 | -2,553 | 697.1 | 1,171 | 1,575 | - |
| Book Value Per Share 2 | - | 1.900 | 2.070 | 1.240 | 1.570 | 1.860 | 2.380 | - |
| Cash Flow per Share | - | 0.5100 | 0.3700 | - | - | - | - | - |
| Capex 1 | - | 53.5 | 102 | 182 | 215 | 217 | 171 | - |
| Capex / Sales | - | 6.54% | 10.97% | 18.17% | 20.49% | 19.67% | 14.53% | - |
| Announcement Date | 9/2/20 | 3/9/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.4
USD
Average target price
16.75
USD
Spread / Average Target
+46.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -32.34% | 3.23B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -3.97% | 11.66B | |
| -1.42% | 11.72B | |
| -31.75% | 11.77B |
- Stock Market
- Equities
- SHC Stock
- Financials Sotera Health Company
